| Literature DB >> 24688693 |
Samuel Aj Trammell1, Charles Brenner1.
Abstract
Nicotinamide adenine dinucleotide (NAD(+)) is a coenzyme for hydride transfer reactions and a substrate for sirtuins and other NAD(+)-consuming enzymes. The abundance of NAD (+), NAD(+) biosynthetic intermediates, and related nucleotides reflects the metabolic state of cells and tissues. High performance liquid chromatography (HPLC) followed by ultraviolet-visible (UV-Vis) spectroscopic analysis of NAD(+) metabolites does not offer the specificity and sensitivity necessary for robust quantification of complex samples. Thus, we developed a targeted, quantitative assay of the NAD(+) metabolome with the use of HPLC coupled to mass spectrometry. Here we discuss NAD(+) metabolism as well as the technical challenges required for reliable quantification of the NAD(+) metabolites. The new method incorporates new separations and improves upon a previously published method that suffered from the problem of ionization suppression for particular compounds.Entities:
Year: 2013 PMID: 24688693 PMCID: PMC3962138 DOI: 10.5936/csbj.201301012
Source DB: PubMed Journal: Comput Struct Biotechnol J ISSN: 2001-0370 Impact factor: 7.271
Figure 1NAD. Intracellular NAD+ is derived from either de novo synthesis from tryptophan or from salvage of NA, Nam, or NR. In yeast, Nam is converted to NA by nicotinamidase Pnc1p (dotted line). In yeast and vertebrates, NA is phosphoribosylated to NAMN, an intermediate in de novo synthesis, and converted to NAD+ by way of NAAD in a step catalyzed by glutamine-dependent NAD+ synthetase [12]. In vertebrates, Nam conversion to NMN is catalyzed by Nampt [16]. The other source of NMN in yeast and vertebrates is phosphorylation of NR by NR kinases. NR and NAR can be split to the corresponding pyridine bases. NAR phosphorylation yields NAMN. NMN is converted to NAD+ by NMN adenylyltransferase activity, which is reversible. As shown, in vertebrates, NMN must be imported into mitochondria for conversion to NAD+. Enzymatic NAD+ and NADP+ consumption releases the Nam moiety and produces ADPr products. Finally, Nam and NA can be converted to non-salvageable products.
Alkaline separation gradient.
| Time (min) | Solvent B (%) | Column Volumes |
|---|---|---|
| 0 | 5 | - |
| 1.8 | 5 | 1.8 |
| 14 | 54 | 12.4 |
| 14.1 | 90 | - |
| 17.1 | 90 | 3 |
| 17.2 | 5 | - |
| 32.2 | 5 | 15.3 |
Acidic separation gradient.
| Time (min) | Solvent B (%) | Column Volumes |
|---|---|---|
| 0 | 5 | - |
| 1.8 | 5 | 1 |
| 11.2 | 35.9 | 5.4 |
| 11.3 | 90 | - |
| 13.3 | 90 | 1.2 |
| 13.4 | 5 | - |
| 23.4 | 5 | 5.8 |
Figure 2Chromatograms of all 19 metabolites generated from injection of complex standard solutions using MRM LC-MS. All compounds were detected in positive ion mode in alkaline (A) and acidic (B) separations. Multiple peaks observed in Uridine and NA illustrate cross talk from other metabolites in mixture. In the case of Uridine, the early eluting peak is the result of the 13C peak of Cytidine. NA later eluting peaks are the result of 13C peaks from Nam produced either from the Nam standard or on-source fragmentation of NR to Nam.
LCMS/MS SRM parameters, sensitivity, and robustness for each metabolite.
| Metabolite | Transition (m/z) | CE | Cone volt. | RT (min) |
| LOQ this study (pmol) | LOQ Evans (pmol) | R2 | RSD | RSD |
|---|---|---|---|---|---|---|---|---|---|---|
| Nam | 123 > 96 | 16 | 32 | 9.82 | 6 | 0.6 | 0.45 | 0.996 | 2 | 1 |
| NA | 124 > 53 | 26 | 32 | 8.35 | 5 | 2.5 | 1.2 | 0.999 | 2 | 1 |
| Cytidine | 244 > 112 | 18 | 18 | 11.14 | 7 | 0.01 | 0.1 | 0.995 | 22 | 16 |
| Uridine | 245 > 113 | 16 | 18 | 11.5 | 7 | 3.1 | 1.2 | 0.99 | 7 | 3 |
| NR | 255 > 123 | 12 | 14 | 8.98 | 5.4 | 0.01 | 0.2 | 0.998 | 4 | 2 |
| NAR | 256 > 124 | 13 | 14 | 10.33 | 6.4 | 0.1 | 0.06 | 0.948 | 11 | 12 |
| Inosine | 269 > 137 | 12 | 12 | 12.88 | 8.2 | 0.03 | 0.07 | 0.974 | 10 | 5 |
| CMP | 324 > 112 | 22 | 16 | 2.97 | 1.1 | 0.09 | 0.68 | 1 | 9 | 1 |
| UMP | 325 > 97 | 12 | 20 | 4.11 | 1.9 | 0.06 | 0.21 | 0.99 | 6 | 4 |
| NMN | 335 > 123 | 12 | 16 | 8.92 | 5.4 | 1 | 0.5 | 1 | 8 | 3 |
| NAMN | 336 > 124 | 12 | 18 | 4.2 | 2 | 0.06 | 0.18 | 0.999 | 10 | 2 |
| IMP | 349 > 137 | 22 | 14 | 9.65 | 5.9 | 0.1 | 0.13 | 0.995 | 6 | 3 |
| ADP | 428 > 136 | 26 | 30 | 10.43 | 6.5 | 0.03 | NIRf | 0.999 | 8 | 3 |
| ATP | 508 > 410 | 16 | 30 | 10.51 | 6.5 | 1 | NIRf | 0.995 | 11 | 3 |
| ADPr | 560 > 348 | 16 | 26 | 11.08 | 6.9 | 0.02 | NIRf | 0.991 | 3 | 4 |
| NAD+ | 664 > 428 | 26 | 26 | 13.64 | 8.7 | 0.19 | 0.17 | 0.999 | 8 | 2 |
| NAAD | 665 > 428 | 24 | 24 | 11.89 | 7.5 | 0.02 | 0.26 | 0.998 | 12 | 2 |
| NADH | 666 > 649 | 20 | 26 | 12.98 | 12 | 0.19 | 0.06 | 0.988 | 10 | 3 |
| NADP | 744 > 604 | 18 | 26 | 12.01 | 7.6 | 0.06 | 0.87 | 0.996 | 13 | 3 |
| NADPH | 745 > 729 | 48 | 28 |
collision energy
LOQ of method described in this paper
LOQ of method in [3]
RSD expressed as percentage of the mean
NAD+/ metabolome of LN428/MPG Cell Line.
| Metabolite | LN428/MPG Cells (µM) |
|---|---|
| ATP | 1010 ± 380 |
| ADP | 890 ± 150 |
| UMP | 370 ± 80 |
| NAD+ | 260 ± 40 |
| Inosine | 250 ± 150 |
| Uridine | 210 ± 80 |
| CMP | 170 ± 70 |
| IMP | 98 ± 26 |
| NADP | 57 ± 10 |
| Nam | 39 ± 2 |
| Cytidine | 6.7 ± 4.4 |
| NADH | 6.7 ± 2.3 |
| ADPr | 6.7 ± 2.2 |
| NMN | 1.3 ± 0.3 |
| NA | <4.0 |
| NR | <0.016 |
| NAMN | <0.68 |
| NAAD | <0.24 |
| NAR | <1.1 |
| NAD+/NADH | 39 |